ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 140 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.08 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $384,232 | -49.6% | 72,360 | -9.6% | 0.00% | – |
| Q2 2023 | $762,686 | -53.3% | 80,030 | -46.1% | 0.00% | -100.0% |
| Q1 2023 | $1,633,500 | +186.7% | 148,500 | +285.7% | 0.00% | – |
| Q4 2022 | $569,800 | +5.3% | 38,500 | +36.0% | 0.00% | – |
| Q3 2022 | $541,000 | -10.3% | 28,300 | 0.0% | 0.00% | – |
| Q2 2022 | $603,000 | +54.2% | 28,300 | +39.4% | 0.00% | – |
| Q1 2022 | $391,000 | -7.1% | 20,300 | 0.0% | 0.00% | – |
| Q4 2021 | $421,000 | -6.2% | 20,300 | +8.0% | 0.00% | – |
| Q3 2021 | $449,000 | -12.5% | 18,800 | 0.0% | 0.00% | – |
| Q2 2021 | $513,000 | +29.5% | 18,800 | +37.2% | 0.00% | – |
| Q1 2021 | $396,000 | -10.8% | 13,700 | -13.3% | 0.00% | – |
| Q4 2020 | $444,000 | -80.0% | 15,800 | -79.1% | 0.00% | -100.0% |
| Q3 2020 | $2,217,000 | -5.2% | 75,664 | -2.2% | 0.00% | 0.0% |
| Q2 2020 | $2,339,000 | +14.0% | 77,364 | +12.4% | 0.00% | 0.0% |
| Q1 2020 | $2,051,000 | – | 68,836 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| FRAZIER MANAGEMENT LLC | 10,542,790 | $314,175,000 | 35.62% |
| Bain Capital Life Sciences Investors, LLC | 3,979,292 | $118,583,000 | 20.06% |
| Omega Fund Management, LLC | 844,680 | $25,171,000 | 10.42% |
| Vivo Capital, LLC | 1,686,527 | $50,259,000 | 4.55% |
| Orbimed Advisors | 4,673,850 | $139,281,000 | 2.34% |
| RA Capital Management | 1,165,184 | $34,722,000 | 1.10% |
| Polar Capital LLP | 375,000 | $11,175,000 | 0.12% |
| CAAS CAPITAL MANAGEMENT LP | 22,413 | $668,000 | 0.07% |
| FMR LLC | 5,713,343 | $170,258,000 | 0.02% |
| Laurion Capital Management LP | 50,000 | $1,490,000 | 0.02% |